Skye Bioscience, Inc.

NasdaqCM: SKYE · Healthcare

Positivity Index

#6,567 / 6,774

Global

#3,811 / 4,000

United States

Positivity Score

-25,466

Rank→

PosiRed: 3 active red flags (highest severity 6/10) View flag history →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 19 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 15 May 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 19 Mar 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

Skye Bioscience, Inc. — Overview & Financial Snapshot

Skye Bioscience, Inc. (NasdaqCM: SKYE) is a Healthcare company, ranked #6,567 of 6,774 companies globally and #3,811 of 4,000 in United States on PositoAI, with a Positivity Score of -25,466. Its market capitalisation is ₹67.70 Cr ($7.17M), P/E ratio is -0.2 and P/B ratio is -14.42. It currently has 3 active red flags (PosiRed) and no yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

What does Skye Bioscience, Inc. do?

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting…

What is Skye Bioscience, Inc.'s P/E and P/B ratio?

Skye Bioscience, Inc. has a P/E ratio of -0.2 and a P/B ratio of -14.42.

What is Skye Bioscience, Inc.'s debt-to-equity ratio?

Skye Bioscience, Inc. has a debt-to-equity ratio of 0.01.

How much does Skye Bioscience, Inc. owe compared with what it owns?

Skye Bioscience, Inc. owes $1.05 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.

What is Skye Bioscience, Inc.'s Positivity rank?

Skye Bioscience, Inc. is ranked #6,567 of 6,774 companies globally and #3,811 of 4,000 in United States on PositoAI, with a Positivity Score of -25,466.

Does Skye Bioscience, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

Yes. Skye Bioscience, Inc. has 3 active red flags (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 19 Aug 2026); Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 15 May 2026); Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 19 Mar 2026). It has no yellow flags.

Where can I read the latest news about Skye Bioscience, Inc.?

Recent headlines about Skye Bioscience, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Skye Bioscience, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Skye Bioscience, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.